Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 8273 - 8280 of 12093 results
Protections of the Newly Enacted Defend Trade Secrets Act
May 12, 2016| Blog| Viewpoint
Good News on “Bad Boy” Guarantees – IRS Reverts to Prior Position in Recent Legal Advice Memorandum
May 12, 2016| Alert| Viewpoint
Just as the Comment Period for "Natural" Ends, FDA Announces Intent to Re-Examine What It Means to Be a "Healthy" Food
May 12, 2016| Blog| Viewpoint
Federal Court Relies on “Evolving Landscape of Health Care” Post-Affordable Care Act to Reject FTC Challenge to Hospital Merger
May 11, 2016| Advisory| Viewpoint
Clearly Defining the Essential Functions of the Job Can Make or Break An ADA Case
May 10, 2016| Blog| Viewpoint
Pescetarian’s Delight: Ninth Circuit Extends Non-Compete Term Beyond Contractual Period
May 10, 2016| Blog| Viewpoint
3 Ways To Prepare For The New Foreign Student Work Rule
May 10, 2016| News
U.S. Solar Installations Reach 1 Million
May 9, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|